AMARIN SHARE PRICE / NASDAQ

13.25 USD

-0.97%

June 13, 2025, 16:00 EDT

Invested in the Future of Cardiovascular Medicine

Our purpose is driven by our vision to stop cardiovascular disease from being a leading cause of death worldwide. Amarin is a global pharmaceutical company developing new treatments to fight against cardiovascular disease. Amarin is relentless in its pursuit of scientific breakthroughs that can lead to revolutionary treatments to create a healthier world. Find out more about who we are, what we stand for and how we are making a difference in the lives of patients.
Quarterly Earnings Q4 2024
plus icon
Quarterly Earnings Q3 2024
plus icon
Quarterly Earnings Q2 2024
plus icon

Upcoming Events and Latest Presentations

Click a link below for access to our events.

07 May 2025

Amarin Corporation’s First Quarter 2025 Results

12 Mar 2025

Amarin Corporation’s Fourth Quarter & Full Year 2024 Results

14 Nov 2024

Amarin Corporation’s Virtual Analyst & Investor Day 2024

30 Oct 2024

Amarin Corporation’s Third Quarter 2024 Results

31 Jul 2024

Amarin Corporation’s Second Quarter 2024 Results

20 May 2024

H.C. Wainwright 2nd Annual BioConnect Investor Conference

01 May 2024

Amarin Corporation’s First Quarter 2024 Results

29 Feb 2024

Amarin Corporation’s Fourth Quarter and Full Year 2023 Results

arrow left icon
arrow right icon

Latest News From Amarin

From research results, financial toolkits and webcasts to important investor information and financial governance. Find out the latest financial news about Amarin in these publications.

05/07/2025
Amarin Reports First Quarter 2025 Financial Results
minus icon
-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA ® /VAZKEPA ® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20
04/29/2025
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
plus icon
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained
04/28/2025
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
plus icon
DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2025 results followed by Q&A on

Investor Contact Form

For corporate governance, analyst coverage, stock information, secretarial matters and other investor-related queries, please use the Contact form

Financial Information

Balancing Passion with Resolution

Learn more about Amarin’s revenue, expenses, profit and loss, as well as a comprehensive overview of the company’s financial health.

;

Sign-Up for Email Alerts

About Amarin for Investors

Amarin is a leading cardiovascular health pharmaceutical company. As leaders, we apply science, research, passion and global knowledge to ensure we further our vision of stopping cardiovascular disease from being a leading cause of death. In order to achieve this vision, we take a strategic approach to management and financial responsibility.

Corporate Governance

Gain new insights into Amarin’s performance and corporate commitments.

Analyst Coverage

Find out which firms and analysts are covering Amarin.

Stock Information

View real-time stock prices and stock quotes.

About Amarin

A new paradigm in cardiovascular health management

Amarin Corporation is focused on a BOLD vision to stop cardiovascular disease from being a leading cause of death. Find out more about our vision and how we lead the way to better care for those with cardiovascular disease.

Science and Health

Passionate about cardiometabolic science and health

Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.

News and Media

Press releases, news, updates and statements

From reports and reviews to partnerships and innovations, find out more about Amarin's latest news and stories as they stand in the press.

ALL-NP-00016 1/23
Amarin

You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.

The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.

Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.

Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.

This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.

This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.

Information on this website may be revised without any prior notice.